Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Cancer Communications

Table 4 Multivariable logistic analyses of potential benefit factors for pathologic response in terms of tumor-related analysis

Variable	OR (95% CI)	P value^b
Age (> 65 vs. ≤ 65 years)	0.84 (0.30–2.35)	0.743
Primary tumor site (left vs. right)	0.44 (0.21–0.92)	0.030
pN category (pN1-2 vs. pN0)	1.04 (0.56–1.91)	0.903
CEA decline (yes vs. no)^a	0.48 (0.24–0.94)	0.032
Metastases presentation (metachronous vs. synchronous)	0.72 (0.30–1.74)	0.462
Size of metastases (< 2.5 vs. ≥ 2.5 cm)	0.50 (0.27–0.92)	0.025
Resection status (R1–2 vs. R0)	1.09 (0.56–2.13)	0.794
Preoperative chemotherapy backbone (CT with Bev vs. CT only)	0.29 (0.10–0.83)	0.021
Preoperative chemotherapy backbone (CT with Cet vs. CT only)	1.79 (0.86–3.73)	0.120
Duration of preoperative chemotherapy (long vs. short)	0.28 (0.14–0.53)	< 0.001

CEA carcinoembryonic antigen, CT chemotherapy, Bev bevacizumab, Cet cetuximab
^a Because initial CEA levels were unavailable, 30 of 159 patients (85 of 380 available tumors) were not evaluable for CEA variations
^b P < 0.05 was emphasized in italics